Apnimed Inc. (NASDAQ:APMD) made a striking entrance on the Nasdaq on July 31, closing its first session at $25 per share, a 56% premium over its $16 IPO price. The debut pushed the company's market capitalization to roughly $950 million, with after-hours trading showing a slight pullback to $23.
The strong opening reflects robust investor demand for the clinical-stage biopharmaceutical company, which is developing an oral therapy for obstructive sleep apnea (OSA). The stock opened at $22, touched an intraday high of $29.15, and saw a low of $16.12, before settling at $25. Trading volume reached 3.44 million shares, representing nearly 29% of the base offering.
The company expanded its offering to 12 million shares from the initially planned 10 million, boosting its preliminary adjusted market value to approximately $1.0 billion. That valuation is about 69% of Inspire Medical Systems' (NASDAQ:INSP) $1.44 billion market cap. However, Apnimed has no approved products and relies on a single investigational asset, AD109, which is currently under FDA review.
The FDA is expected to render its decision on AD109 by February 28, 2027. The agency initiated formal review in July, a milestone CEO Kevin Lind called "an important step" toward expanding treatment options for OSA patients. Apnimed's preliminary cash position stood at $172.8 million at the end of June, with IPO gross proceeds adding $192 million, bringing total liquidity to roughly $364.8 million before fees.
Clinical data for AD109 show consistent efficacy across two Phase 3 trials. In the SynAIRgy study, the drug reduced the apnea-hypopnea index (AHI) by 44.1% versus 17.6% for placebo, a 26.5 percentage-point difference. The LunAIRo trial showed a 33.7% reduction versus 7.3%, a similar 26.4-point gap. However, tolerability was a concern: the discontinuation rate due to adverse events in SynAIRgy was 21.2% versus 3.1% for placebo, nearly seven times higher. Fatigue outcomes showed no significant statistical benefit.
The company's valuation now sits alongside established OSA players. Inspire Medical Systems, which offers an implanted nerve stimulator, trades at $1.44 billion. ResMed (NYSE:RMD), the CPAP device leader, commands a $30.74 billion market cap. Eli Lilly (NYSE:LLY), whose Zepbound injection is FDA-approved for OSA in obese adults, has a market value exceeding $1 trillion, though that reflects its broader drug portfolio.
Apnimed's oral pill could offer a convenient alternative to existing therapies if approved and well-tolerated in real-world use. The company's market debut coincided with a 1.6% weekly gain in the Nasdaq Composite, but its own performance dwarfed that benchmark.
The offering is set to close on August 3, and investors will watch Eli Lilly's second-quarter earnings on August 5 for commentary on Zepbound demand, which may influence sentiment on the OSA treatment landscape.
Risks remain significant. The FDA could delay, restrict, or reject AD109. Apnimed has no commercial revenue and posted a $128.2 million loss in 2025. High discontinuation rates could hamper adoption. The after-hours dip, though on light volume, suggests volatility ahead. The market's enthusiasm may be pricing in optimism that could quickly unravel if the regulatory path hits a snag.
